CSL Limited CSLLY OTC

CSL Limited (CSLLY) reported total assets of $39.4B and total liabilities of $18B for fiscal year 2025, resulting in total equity of $21.48B.

The company held $2.16B in cash and short-term investments. Total debt stood at $11.5B, with net debt of $9.34B. The Debt-to-Equity (D/E) ratio was 0.54 (moderate).

Current ratio is 2.46, indicating strong short-term liquidity. Interest coverage is 6.5x (adequate).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (75/100) — Total assets $39.4B and equity $21.48B support the company's competitive scale
• VALUE (62/100) — Debt-to-Equity 0.54 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 77/100 with 6/7 criteria passed.

NONOF

Novo Nordisk A/S

$40.22

+3.62%

CMXHF

CSL Limited

$96.69

-4.43%

RVMD

Revolution Medicines, Inc.

$152.54

+3.76%

BGNE

BeiGene, Ltd.

$184.71

+0.49%

CERE

Cerevel Therapeutics Holdings, Inc.

$44.96

+0.74%

NUVL

Nuvalent, Inc.

$104.75

-0.26%

COGT

Cogent Biosciences, Inc.

$36.32

-0.47%

KNSA

Kiniksa Pharmaceuticals, Ltd.

$45.89

-2.20%